✦ LIBER ✦

Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis

✍ Scribed by AliceB. Gottlieb; Bruce Miller; Nicholas Lowe; William Shapiro; Charles Hudson; Ross Bright; Mark Ling; Anna Magee; CalvinO. McCall; Toivo Rist; Wolfgang Dummer; Patricia Walicke; RobertJ. Bauer; Mark White; Marvin Garovoy

Book ID: 106297947
Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 230 KB
Volume: 7
Category: Article
ISSN: 1203-4754
DOI: 10.1007/s10227-002-0118-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label study to evaluate the safe

An open-label study to evaluate the safety and efficacy of 1.0 mg/kg subcutaneously administered efalizumab in adults with moderate to severe hand or foot psoriasis

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Efficacy and Safety of Efalizumab in Pat

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

✍ Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dube 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

Safety and efficacy of subcutaneous cert

Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB